COMPOSITION POUR ATTÉNUER, PRÉVENIR OU TRAITER UN TROUBLE DU SOMMEIL OU COMPOSITION POUR SUPPRIMER LA RÉSISTANCE À UN AGONISTE DU SITE DE LIAISON AUX BENZODIAZÉPINES DU RÉCEPTEUR GABA-A, OU POUR ATTÉNUER UN EFFET SECONDAIRE D'UN AGONISTE DU SITE DE LIAISON AUX BENZODIAZÉPINES DU RÉCEPTEUR GABA-A, CHAQUE COMPOSITION COMPRENANT DU PHLOROGLUCINOL EN TANT QUE PRINCIPE ACTIF
The present invention relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol as an active ingredient and a health functional food composition for ameliorating somnipathy including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention rapidly and reliably induce and maintain sleep, prevent repeated awakenings, unalter physiological sleep architecture, are particularly devoid of residual sedative effects, which could impair daytime functioning and cognitive performance, do not cause tolerance to a conventional agonist at the benzodiazepine binding site of the GABA-A receptor despite long-term administration, and do not cause side effects of a conventional agonist at the benzodiazepine binding site of the GABA-A receptor. The present invention also relates to a pharmaceutical composition for suppressing tolerance to or alleviating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient and a health functional food composition for suppressing tolerance to or ameliorating side effects of an agonist at the benzodiazepine binding site of the GABA-A receptor including phloroglucinol as an active ingredient. The pharmaceutical composition and the health functional food composition according to the present invention can alleviate side effects of the agonist or can suppress tolerance to the agonist resulting from long-term administration. The present invention also relates to a pharmaceutical composition for preventing or treating somnipathy including phloroglucinol and an agonist at the benzodiazepine binding site of the GABA-A receptor as active ingredients. The pharmaceutical composition of the present invention uses a reduced amount of the agonist, which may increase the amount of sleep but degrade the quality of sleep to cause various side effects, to all
